US Court Issues Injunction Against Open-Access Publisher OMICS

The Federal Trade Commission won an initial ruling against the India-based publisher for allegedly misleading researchers and for misrepresenting journal impact factors and editorial boards. 

Nov 27, 2017
Katarina Zimmer

ISTOCK, SEZERYADIGARLast week (November 22), the Federal Trade Commission (FTC) announced that it won an initial court ruling against OMICS, a publisher of open-access journals. The preliminary injunction stems from a complaint filed in August 2016 by the FTC against OMICS CEO Srinubabu Gedela, and affiliated companies ImedPub and Conference Series, alleging that they published articles without standard peer review, misrepresented numerous scientists as editors, and made multiple deceptive claims towards researchers.

According to the complaint, OMICS did not disclose to researchers that they would have to pay extraordinarily high publishing fees until articles were accepted for publication. The company also failed to disclose that it calculated its journal impact factors in an unorthodox fashion, FTC claims, and falsely stated that its journals are indexed by federal research databases such as the National Institutes of Health’s PubMed and Medline services.

“The defendants in this case used false promises to convince researchers to submit articles presenting work that may have taken months or years to complete, and then held that work hostage over undisclosed publication fees ranging into the thousands of dollars,” Jessica Rich, Director of the FTC’s Bureau of Consumer Protection, says in a press release. “It is vital that we stop scammers who seek to take advantage of the changing landscape of academic publishing.”

Chief judge in the case, Gloria Navarro of the District Court of Nevada, wrote that the evidence supplied by the FTC is “sufficient to support a preliminary conclusion that Defendants made misrepresentations regarding their journal publishing.”

The defendants will still be able to publish their journals, but they have been ordered to remove misleading claims from their websites, according to the Toronto Star. Navarro found the ruling necessary, writing that “absent such an injunction, the Court finds it likely that Defendants will continue to engage in deceptive practices.”

OMICS Group is an India-based publisher, and claims to put out more than 700 peer-reviewed journals on its website. An investigation by the Toronto Star/CTV News found last year that OMICS had purchased multiple reputable medical journals throughout Canada, which raised concerns among scientists that they were being “hijacked” to publish “junk science for profit.” OMICS had been included on the now-defunct list of predatory publishers compiled by Jeffrey Beall, a librarian at the University of Colorado Denver (archived version).

OMICS CEO Gedela tells the Star after learning of the injunction that he did not believe the allegations being made against the company. The “FTC made allegations based on ‘fake news,’” he says. “We are pretty sure FTC will not be able to prove any of the allegations against us.”

Gregory Ashe, a senior attorney for the FTC’s division of financial practices, tells Retraction Watch that the lawsuit was not intended to regulate the journals or their content, but to combat the deceptive practices. “This is certainly our message to the academic world that, we are monitoring and on the lookout for predatory publishers.”

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb


Sponsored Product Updates

FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
Have you played Pokemon Go? Then you've used Augmented Reality (AR) technology! AR technology holds substantial promise and potential for providing a low-cost, easy to use digital platform for the manipulation of virtual 3D objects, including 3D models of biological macromolecules.